中国药品又一个“专利延期王”诞生

药智网
18 Jun

近日,荣昌生物宣布收到国家知识产权局下发的《药品专利权期限补偿审批决定》,称其核心产品泰它西普注射液获1827天专利补偿,保护期从2027年6月15日延长至2032年6月15日。值得注意的是,这是我国2021年新《中华人民共和国专利法》(下称《专利法》)实施以来,药品行业又一个达成“顶格补偿”的案例。制度突破自2021年6月1日起,我国新《专利法》生效,其中增加了关于药品专利权期限补偿的条款。《...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10